Niosomal Delivery of Celecoxib and Metformin for Targeted Breast Cancer Treatment

SIMPLE SUMMARY: This study investigates the therapeutic efficacy of combining Metformin (MET) and Celecoxib (CXB) in the treatment of breast cancer. Niosomes, which are drug carriers, were prepared using the thin-film hydration technique. These niosomes were characterized and found to have stable properties when stored at 4 °C for three months. The encapsulated drugs in the niosomes showed increased cytotoxicity compared to their free drug counterparts in both two-dimensional and three-dimensional viability assays. The combination of Metformin Niosomal Particles (MET NPs) and Celecoxib Niosomal Particles (CXB NPs) also led to decreased cell viability in both models. However, the efficacy of the niosomes’ combination was not superior to that of the free drug combination in preventing cell migration. Overall, this study provides valuable insights into the potential application of combining MET and CXB nanoparticle delivery systems for breast cancer treatment. ABSTRACT: Breast cancer continues to be a prominent worldwide health concern and requires continued investigation into innovative therapeutic approaches. Here, we report the first investigation into the therapeutic efficacy of combining Metformin (MET) and Celecoxib (CXB), both in free and niosomal form, for the treatment of breast cancer. Our investigation encompassed the characterization of these niosomal drug carriers, their stability assessment, and their effect on breast cancer cell models. The thin-film hydration technique was employed to prepare niosomes with spherical, uniform-size distributions and high encapsulation efficiencies. The niosomes were characterized by TEM, particle size analyzer, and ATR-FTIR. The niosomes with an average size of 110.6 ± 0.6 and 96.7 ± 0.7, respectively, for MET and CXB were stable when stored at 4 °C for three months with minimal drug leakage, minor changes in encapsulation efficiency and size, and unchanged physicochemical parameters. Evaluation in two-dimensional (2D) and three-dimensional (3D) viability assays demonstrated an increased cytotoxicity of encapsulated drugs when compared to their free-drug counterparts. Additionally, the combination of Metformin Niosomal Particles (MET NPs) and Celecoxib Niosomal Particles (CXB NPs) led to decreased cell viability in both 2D and 3D models compared to each drug administered individually. When comparing the effect of the niosomal versus the free combination of the drugs on cell migration, we found that both interventions effectively prevented cell migration. However, the efficacy of the niosomes’ combination was not superior to that of the free drug combination (p < 0.05). In conclusion, the results of this study provide valuable insights into the potential application of combining MET and CXB nanoparticle delivery systems to breast cancer treatment. Exploring the in vivo application of this drug delivery system could open new avenues for more effective and targeted therapeutic approaches for breast cancer patients.